Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1430120 | 0.71 | — | — | |
| SCHEMBL13670531 | 0.68 | — | — | |
| SCHEMBL17723544 | 0.65 | KDM4E (0.60) | ALPLSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL12410814 | 0.64 | ADRA2A (0.41) | SMN1; SMN2 | |
| SCHEMBL18355749 | 0.62 | GRM5 (0.33) | — | |
| SCHEMBL22328207 | 0.61 | — | — | |
| SCHEMBL1091034 | 0.60 | — | — | |
| SCHEMBL14827602 | 0.60 | PDPK1 (0.66) | CYP1A2MAPK1 | |
| SCHEMBL2488875 | 0.60 | ALPL (0.56) | ALPLSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL2592305 | 0.60 | TSHR (0.50) | ALPLKDM4EMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | ALPL 2387/4885SMN1; SMN2 4528/4885NPC1 173/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | ALPL 2387/4885SMN1; SMN2 4528/4885NPC1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.